Techh.info/techtechnology hourly

Immunotherapy

headlines texts
15.05.2019
19:47 Medscape.ComFDA Okays Another Immunotherapy Plus TKI for Advanced RCC

The FDA has approved avelumab in combination with the tyrosine kinase inhibitor (TKI) axitinib for the first-line treatment of advanced renal cell carcinoma (RCC).

Скрыть анонс
13.05.2019
18:55 CancerNetwork.comNatural Killer Cell Levels Could Influence Immunotherapy Outcomes for Lymphoma

Patients with follicular lymphoma or diffuse large B-cell lymphoma with a low peripheral blood natural killer cell count at baseline had shorter time to progression.

Скрыть анонс
10.05.2019
11:18 ClinicalOncology.comAntibiotics May Blunt Cancer Immunotherapy Response

San Francisco—Cancer patients who received antibiotics within 60 days of starting immunotherapy were significantly less likely to respond to cancer treatment than those not receiving antibiotics, researchers reported at the 2019 Gastrointestinal Cancers Symposium.

Скрыть анонс
07.05.2019
22:49 ScienceDaily.comTumor mutations may predict response to immunotherapy

Researchers say they have found a potential explanation for the failures.

Скрыть анонс
06.05.2019
22:38 Nanowerk.comNanovaccine design can dramatically improve cancer immunotherapies

Effectiveness depends on molecular architecture and 3D presentation of components.

Скрыть анонс
22:01 Phys.orgVaccine design can dramatically improve cancer immunotherapies

When it comes to the effectiveness of nanotherapeutic vaccines, shape matters.

Скрыть анонс
03.05.2019
15:31 CancerNetwork.comReview Touts Benefits of Immunotherapy for Non-Melanoma Skin Cancers

The authors discuss the potential use and limitations of immunotherapy among patients with squamous cell cancer, basal cell carcinoma, and other skin cancers.

Скрыть анонс
10:08 Technology.orgResearchers Find New Target to Improve Response to Cancer Immunotherapy

New findings suggest an unexpected path to killing cancer cells could make the hottest cancer treatment — immunotherapy

Скрыть анонс
02.05.2019
17:38 ScienceDaily.comPretreatment with TNF inhibitors may improve outcomes of combination cancer immunotherapy

This study proposes a new therapeutic approach against cancer that dissociates efficacy and toxicity in the use of combined immunotherapy in animal models. This clinical strategy consists of blocking TNF protein while applying combination immunotherapy treatment (inhibition therapy of PD-1 and CTLA-4, other proteins that 'slow down' the immune response).

Скрыть анонс
10:22 Reuters.com HealthAstraZeneca ties up with France's Transgene to develop viral immunotherapies

British drugmaker AstraZeneca Plc and French biopharmaceutical firm Transgene SA entered into an agreement on Thursday to co-develop five cancer-killing viral immunotherapies.

Скрыть анонс
01.05.2019
22:54 ScienceDaily.comNew target to improve response to cancer immunotherapy

Researchers have looked at a little-understood type of cell death called ferroptosis. They found ferroptosis occurs in tumor cells and plays a role in cancer immunity, suggesting the potential of targeting this pathway to improve immunotherapy treatments.

Скрыть анонс
20:17 Nature.ComProphylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy

Скрыть анонс
20:17 Nature.ComCD8

Скрыть анонс
30.04.2019
22:43 Medscape.ComPeanut Oral Immunotherapy May Increase Risk for Anaphylaxis

A new review finds that oral immunotherapy for peanut allergy may result in desensitization but is associated with more anaphylaxis events.

Скрыть анонс
18:05 CancerNetwork.comCombo Immunotherapy Failed to Improve Outcomes in MSS Colorectal Cancer

A phase III trial examined immunotherapy in patients with microsatellite-stable metastatic colorectal cancer.

Скрыть анонс
11:08 News-Medical.NetAngiotensin receptor blockers could improve response to cancer immunotherapy

A research team led by investigators at Massachusetts General Hospital and the Massachusetts Institute of Technology has found that combining a specialized version of an antihypertension drug with immune checkpoint blockers could increase the effectiveness of cancer immunotherapies.

Скрыть анонс
29.04.2019
07:14 GizmagMeta-study suggests peanut immunotherapy may actually increase allergic reactions


A systematic meta-analysis of a dozen trials into the efficacy of an oral immunotherapy treatment designed to reduce allergic reactions to peanuts has concluded the treatment may work in clinical environments however it paradoxically results in patients suffering from more real-world adverse allergic events than people who simply avoided peanuts altogether.
.. Continue Reading Meta-study suggests peanut immunotherapy may actually increase allergic reactions Category: Health & Wellbeing Tags: Allergies Immunotherapy Peanut

Скрыть анонс
04:58 CancerNetwork.comRecent Clinical Trials Explore Immunotherapies for Urothelial Carcinoma

Dr. Balar highlights promising evidence on the potential benefits of the use of immunotherapy in the advanced bladder cancer setting.

Скрыть анонс
04:58 CancerNetwork.comCombining Chemotherapy and Immunotherapy for the Treatment of Triple-Negative Breast Cancer

Dr. McArthur discusses the latest results of immunotherapy trials in the treatment of triple-negative breast cancer.

Скрыть анонс
26.04.2019
19:23 Google news HealthOral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety - The Lancet

Oral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety  The LancetPeanut Allergy Immunotherapy Increases Anaphylaxis Risk: Study  The ScientistPeanut exposure may not work for peanut allergy  NewsyA Promising Peanut Allergy Treatment May Not Work So Well After All, Research Review Says  TIMEExperimental treatment for peanut allergy increases anaphylaxis risk, study finds  CNNView full coverage on Google News

Скрыть анонс
19:23 Google news Sci/TechOral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety - The Lancet

Oral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety  The LancetPeanut Allergy Immunotherapy Increases Anaphylaxis Risk: Study  The ScientistPeanut exposure may not work for peanut allergy  NewsyA Promising Peanut Allergy Treatment May Not Work So Well After All, Research Review Says  TIMEExperimental treatment for peanut allergy increases anaphylaxis risk, study finds  CNNView full coverage on Google News

Скрыть анонс
13:01 Technology.orgStudy pinpoints what causes relapse after cancer immunotherapy

Harnessing the body’s immune system to fight off cancer, a tactic known as immunotherapy, has tremendously improved outcomes

Скрыть анонс
03:36 Drugs.comIs Peanut Allergy 'Immunotherapy' Causing More Harm Than Good?

THURSDAY, April 25, 2019 -- The idea behind immunotherapy for peanut allergy is appealing in its simplicity: Ask a patient to eat tiny amounts of peanut every day, and over time their immune system will become desensitized to it. Unfortunately, this...

Скрыть анонс
01:54 NewScientist.ComPeanut allergy immunotherapy may actually do more harm than good

Treatments intended to desensitise people to peanuts had shown promise in tests, but an analysis suggests they may make dangerous allergic reactions more likely

Скрыть анонс
17.04.2019
19:01 ScienceDaily.comOral immunotherapy safe for preschool-aged children with peanut allergies, study suggests

New data suggests that oral immunotherapy offered as routine treatment in a hospital or clinic is safe for preschool-aged children with peanut allergies.

Скрыть анонс
16:44 StemCellsPortal.comlCancers 'change spots' to avoid immunotherapy

LONDON (UK), April 2019 — Cancers can make themselves harder for new immunotherapies to see by “changing their spots” — and switching off a key molecule on the surface of cells that is otherwise recognized by treatment.
Researchers found that they could test samples from patients with bowel cancer to identify which were most likely to respond to immunotherapy by assessing molecular changes within miniature tumors grown in the laboratory.
Using the mini tumors, the researchers identified existing drugs that could potentially be used in combination with immunotherapy to make it work for many more patients.
The team at the Institute of Cancer Research (ICR), London, and the Royal Marsden NHS Foundation Trust believe their findings could help increase the effectiveness of the antibody-based drug cibisatamab and open up ways of assessing whether patients will respond to immunotherapy

Скрыть анонс
15.04.2019
17:40 ScienceDaily.comCancers 'change spots' to avoid immunotherapy

Cancers can make themselves harder for new immunotherapies to see by 'changing their spots' -- and switching off a key molecule on the surface of cells that is otherwise recognised by treatment.

Скрыть анонс
09:54 News-Medical.NetCancer cells use tactics to avoid being recognised by immunotherapy agents

Researchers have found that bowel cancer cells have a mechanism by which they can switch off some key molecules on their surfaces and thus escape being recognised and killed by the immunotherapy agents.

Скрыть анонс
07:39 News-Medical.NetCancers avoid immunotherapies by 'changing their spots'

Cancers can make themselves harder for new immunotherapies to see by 'changing their spots' - and switching off a key molecule on the surface of cells that is otherwise recognized by treatment.

Скрыть анонс
12.04.2019
16:46 StemCellsPortal.comlImmunotherapy kicks, kills HIV by exploiting common virus

PITTSBURGH, , A (US), April 2019 — In a first on the quest to cure HIV, University of Pittsburgh Graduate School of Public Health scientists report in EBioMedicine that they’ve developed an all-in-one immunotherapy approach that not only kicks HIV out of hiding in the immune system, but also kills it.
The key lies in immune cells designed to recognize an entirely different virus. 
The discovery, made in the laboratory using cells from people with HIV, is yet to be tested in clinical trials, but could lead to the development of a vaccine that would allow people positive for HIV to stop taking daily medications to keep the virus in check.  
“A lot of scientists are trying to develop a cure for HIV, and it’s usually built around the ‘kick and kill’ concept – kick the virus out of hiding and

Скрыть анонс
08.04.2019
17:46 News-Medical.NetNew clinical trials to investigate combination immunotherapy for treating advanced cancers

City of Hope physician-scientists recently opened two clinical trials to investigate a combination of cytokines and immunotherapy that may be able to transform nearly-impossible-to-treat cancer into a disease that can be corralled into remission.

Скрыть анонс
11:54 Technology.orgImmunotherapy Kicks, Kills HIV by Exploiting a Common Virus

In a first on the quest to cure HIV, University of Pittsburgh Graduate School of Public Health scientists report in EBioMedicine that

Скрыть анонс
05:31 News-Medical.NetNew HIV drug that is like a "Swiss Army knife of immunotherapies"

HIV is a tricky virus that causes a unique phenomenon where the virus hides within the immune cells of patients when they are on treatment with the antiretroviral therapy (ART) drugs. When they are off the drugs, the virus comes back.

Скрыть анонс
05.04.2019
22:07 ScienceMag.orgFecal transplants could help patients on cancer immunotherapy drugs

Early results hint that benefits seen in mice could extend to people

Скрыть анонс
17:08 News-Medical.NetPatients on immunotherapies should consume more fiber, fewer probiotics

A new study has found that taking probiotics could drastically reduce the response of cancer patients to immunotherapy. Patients on a fiber-rich diet showed a five-fold increase in response.

Скрыть анонс
13:04 CancerNetwork.comPrecursor Immunotherapy to Prevent Squamous Cell Carcinoma

Researchers evaluated whether treatment with calcipotriol plus 5-fluorouracil aided in reducing the risk of squamous cell carcinoma.

Скрыть анонс
11:49 Technology.orgUrine Test to Evaluate Immunotherapy Success Gets $1.8 Million NIH Research Grant

New immunotherapies can dramatically defeat cancer. But more often, cancer evades them, and doctors need to know quickly

Скрыть анонс
04.04.2019
19:53 MedicalNewsToday.comMedical News Today: Cancer: Are probiotics making immunotherapy less effective?

Probiotic supplements could be having a detrimental effect on this particular form of cancer treatment, according to new research.

Скрыть анонс
18:40 ScienceDaily.comImmunotherapy kicks and kills HIV by exploiting a common virus

In a first on the quest to cure HIV, scientists report that they've developed an all-in-one immunotherapy approach that not only kicks HIV out of hiding in the immune system, but also kills it. The key lies in immune cells designed to recognize an entirely different virus.

Скрыть анонс
09:23 News-Medical.NetNew all-in-one immunotherapy approach kicks out hiding HIV and also kills it

In a first on the quest to cure HIV, University of Pittsburgh Graduate School of Public Health scientists report today in EBioMedicine that they've developed an all-in-one immunotherapy approach that not only kicks HIV out of hiding in the immune system, but also kills it.

Скрыть анонс
03.04.2019
08:44 JapanTimes.co.jpImmunotherapy: The key to a brighter future for cancer patients in Japan’s aging society?

As the risk of cancer increases among the country’s aging population, immunologist Tasuku Honjo is pinning his hopes on cancer treatments that shift the approach ...

Скрыть анонс
05:49 ScienceDaily.comIs your melanoma hot enough for immunotherapy?

A new study shows that tumors with mutations in genes leading to over-activation of the NF-kB signaling pathway were more than three times as likely to respond to anti-PD1 immunotherapy compared with tumors in which these changes were absent.

Скрыть анонс
01.04.2019
22:10 StemCellsPortal.comlHarnessing T-cell “stemness” could enhance cancer immunotherapy

BETHESDA, MD (US), March 2019 — A new study led by scientists in the Center for Cancer Research (CCR) at the National Cancer Institute (NCI) sheds light on one way that tumors may continue to grow despite the presence of cancer-killing immune cells. The findings, published March 29 in Science, suggest a way to enhance the effectiveness of immunotherapies for cancer treatment. NCI is part of the National Institutes of Health.
Dying cancer cells release the chemical potassium, which can reach high levels in some tumors. The research team reported that elevated potassium causes T cells to maintain a stem cell-like quality, or “stemness,” that is closely tied to their ability to eliminate cancer during immunotherapy. The findings suggest that increasing T cells’ exposure to potassium — or mimicking the effects of high potassium — could make cancer immunotherapies more effective.
“This

Скрыть анонс
12:54 Technology.orgHarnessing T-cell “stemness” could enhance cancer immunotherapy

A new study led by scientists in the Center for Cancer Research (CCR) at the National Cancer Institute

Скрыть анонс
30.03.2019
21:35 News-Medical.NetETH researchers take major step towards personalized cancer immunotherapy

Cells belonging to the body's own immune system can help fight tumours. For several years now, this has allowed oncologists to use medications known as checkpoint inhibitors to encourage T cells to eliminate tumor cells.

Скрыть анонс
06:42 News-Medical.NetIASLC 2019 Small Cell Lung Cancer Meeting focuses on immunotherapy and patient perspective

While non-small cell lung cancer is the more common form of lung cancer and attracts the lion's share of the research funding, recent developments in small cell lung cancer may be shifting that slightly.

Скрыть анонс
29.03.2019
17:06 CancerNetwork.comNCCN: New Bladder Cancer Guidelines Include Updated Staging, Immunotherapy Options

The updates to the guidelines reflect recent advances, including recommended immunotherapies and changes in tumor staging.

Скрыть анонс
15:59 ScienceDaily.comHarnessing T-cell 'stemness' could enhance cancer immunotherapy

A new study sheds light on one way tumors may continue to grow despite the presence of cancer-killing immune cells. The findings suggest a way to enhance the effectiveness of immunotherapies for cancer treatment.

Скрыть анонс
28.03.2019
20:33 News-Medical.NetTumor biomarker EpCAM shown to be promising target for cancer immunotherapy

Researchers have shown that cancer immunotherapy targeting the tumor biomarker epithelial cell adhesion molecule is safe and nontoxic in mice and can significantly delay tumor formation and growth.

Скрыть анонс
26.03.2019
12:45 Technology.orgTopical immunotherapy keeps skin cancer risk at bay

A combination of two topical creams already shown to clear precancerous skin lesions from sun-damaged skin also lowers

Скрыть анонс
25.03.2019
19:38 ScienceDaily.comWhy immunotherapy is not effective for some patients with metastatic melanoma and kidney cancer

White blood cells known as B cells have been shown to be effective for predicting which cancer patients will respond to immune checkpoint blockade (ICB) therapy, according to a new study.

Скрыть анонс
16:49 CancerNetwork.comNCCN: Updated Guidelines Reflect Advances, ‘Immunotherapy Era’ for Breast Cancer

Among the updates are expanded treatment options, including a recently approved immunotherapy regimen for locally advanced or metastatic disease.

Скрыть анонс
20.03.2019
17:22 CancerNetwork.comSGO 2019: Dendritic Cell–Based Immunotherapy Shows “Dramatic” Response for Ovarian Cancer

The phase II trial evaluated dendritic cell–based immunotherapy with concomitant administration of chemotherapy vs chemotherapy alone.

Скрыть анонс
19.03.2019
09:34 News-Medical.NetGARP protein can be a potential target for immunotherapy against colorectal cancer

Colorectal cancer is the third leading cause of cancer-related deaths in both men and women. Despite significant advances in therapies for this particular cancer, the five-year survival rate is 12 percent, according to the American Cancer Society.

Скрыть анонс
01:57 ScienceDaily.comThe story of GARP: A potential target for cancer immunotherapy

Researchers reveal how the cell surface receptor GARP plays a role in T regulatory cell function and migration to the gut. Because the presence of T regulatory cells in the gut is generally associated with negative outcomes in patients with colorectal cancer, GARP could have potential as a therapeutic target for patients with this type of cancer.

Скрыть анонс
18.03.2019
23:26 Technology.orgPreclinical Data Shows Combination Immunotherapy Could Stop Liver Cancer Growth

Even as overall cancer incidence and mortality decrease in the United States, the number of people diagnosed with

Скрыть анонс
15.03.2019
00:09 ScienceDaily.comHow immunotherapy may be effective for fighting tuberculosis

New research suggests that structures released by infected cells in tuberculosis may be used in tandem with antibiotics to boost the body's immune system, helping fight off the disease.

Скрыть анонс
14.03.2019
10:26 News-Medical.NetPreclinical data shows combination immunotherapy could suppress tumor growth in the liver

Even as overall cancer incidence and mortality decrease in the United States, the number of people diagnosed with liver cancer is on the rise.

Скрыть анонс
13.03.2019
23:23 ScienceDaily.comCombination immunotherapy could stop liver cancer growth

New preclinical data offers proof-of-principle for a combination immunotherapy that suppresses tumor growth in the liver. Current therapies for liver cancer are largely ineffective, resulting in poor outcomes.

Скрыть анонс
11.03.2019
11:40 News-Medical.NetPrecision cancer drugs spark powerful immune response and boost effects of immunotherapy

Precision cancer drugs called PARP inhibitors have a previously unknown ability to boost the immune system, and could help many more patients benefit from immunotherapy, a new study reveals.

Скрыть анонс
09.03.2019
18:08 ScienceDaily.comPrecision drugs could unmask cancers to immune system and boost effects of immunotherapy

Precision cancer drugs called PARP inhibitors have a previously unknown ability to boost the immune system, and could help many more patients benefit from immunotherapy, a new study reveals.

Скрыть анонс
01:56 CNN HealthFDA approves first immunotherapy regimen for breast cancer

The US Food and Drug Administration has granted its first approval to an immunotherapy regimen for breast cancer, the agency announced Friday.

Скрыть анонс
08.03.2019
22:00 Medscape.ComFDA Approves First Immunotherapy for Breast Cancer

For use in advanced triple-negative disease, atezolizumab is approved in combination with the chemotherapy nab-paclitaxel. The pairing improved progression-free survival.

Скрыть анонс
07.03.2019
13:06 News-Medical.NetACROBiosystems collaborates with ProMab Biotechnologies to develop immunotherapy products

ACROBiosystems, a leading manufacturer of recombinant proteins, announced that they have signed a collaboration agreement with ProMab Biotechnologies, a leading manufacturer of monoclonal antibodies and CAR-T cells.

Скрыть анонс
12:46 ClinicalOncology.comImmunotherapy Can Stall Without Supportive Care

Anaheim, Calif.—A young man came to Memorial Sloan Kettering Cancer Center (MSK) looking for help. He had tried multiple treatments for his acute lymphoblastic leukemia (ALL), but a bone marrow biopsy revealed his cancer had returned.

Скрыть анонс
06.03.2019
18:34 CancerNetwork.comTumor Mutational Burden to Guide Immunotherapy in Lung Cancer

A trial showed that tumor mutational burden may be effective as a biomarker in patients treated with immunotherapy.

Скрыть анонс
11:42 News-Medical.NetNuclear medicine imaging assesses melanoma patients' response to immunotherapy

Nuclear medicine imaging with PET/CT can monitor the effectiveness of immunotherapy treatment for metastatic melanoma and predict outcome. In this way, a patient's therapy can be more effectively tailored to his or her personal response.

Скрыть анонс
04.03.2019
04:10 CancerNetwork.comAdding a Vaccine to Immunotherapy in Lung Cancer: Will It Improve Outcomes?

Researchers studied the combination of a cellular vaccine known as HS-110 and nivolumab in an early-phase trial of patients with advanced non–small-cell lung cancer.

Скрыть анонс
28.02.2019
15:06 Technology.orgUsing anti-cancer immunotherapy to fight HIV

Researchers at the University of Montreal Hospital Research Centre (CRCHUM) have shown that immunotherapy treatments against cancer could

Скрыть анонс
25.02.2019
18:56 ScienceDaily.comImmunotherapy for egg allergy may allow patients to eat egg safely long after treatment

After completing up to four years of egg oral immunotherapy (eOIT) treatment, certain participants were able to safely incorporate egg into their diet for five years.

Скрыть анонс
09:38 News-Medical.NetEgg oral immunotherapy could be safe way of desensitizing children, youth with egg allergy

UNC School of Medicine researcher Edwin Kim, MD, MS, says the results of a multi-year observational study are encouraging for those suffering from egg allergies.

Скрыть анонс
09:38 News-Medical.NetRegular dietary peanut consumption after immunotherapy may extend allergy treatment benefits

Regular dietary peanut consumption after completing oral immunotherapy or sublingual immunotherapy for peanut allergy may provide continued protection against accidental exposures to the allergen, according to a new study led by Edwin Kim, MD, who presented the findings at the annual American Academy of Allergy, Asthma and Immunology conference in San Francisco.

Скрыть анонс
20.02.2019
23:34 ScienceDaily.comNew machine learning technique rapidly analyzes nanomedicines for cancer immunotherapy

With their ability to treat a wide a variety of diseases, spherical nucleic acids (SNAs) are poised to revolutionize medicine. But before these digitally designed nanostructures can reach their full potential, researchers need to optimize their various components.

Скрыть анонс
22:09 FierceBiotech.comUsing Bristol-Myers’ popular leukemia drug to improve anti-PD-1 cancer immunotherapy

Because not all patients respond to anti-PD-1/L1 therapies, researchers are exploring new ways to improve their efficacy. Now, a team led by Cedars-Sinai Medical Center scientist has pinpointed Sprycel, a popular blood cancer drug by Bristol-Myers Squibb, as a potential booster.

Скрыть анонс
20:17 News-Medical.NetImmunotherapeutic antibody therapy to kill cancer has now progressed to patient testing

Developed by researchers at the University of Turku in Finland, an immunotherapeutic antibody therapy re-educates macrophages to activate passivated cytotoxic T cells to kill cancer. The antibody therapy prevented the growth of tumors in several mouse models.

Скрыть анонс
15:44 MedicalNewsToday.comMedical News Today: Aggressive brain cancer: Why does immunotherapy fail?

New research helps explain why some glioblastoma tumors respond to immunotherapy whereas the majority of these aggressive cancers do not.

Скрыть анонс
03:26 ScienceDaily.comBirch pollen allergen immunotherapy normalizes nasal gene-expression and microbial community

According to a new study, birch pollen allergen immunotherapy modifies the gene expression and microbiome profile of the nasal epithelium to correspond to those of healthy controls.

Скрыть анонс
19.02.2019
23:44 Nanowerk.comNew machine learning technique rapidly analyzes nanomedicines for cancer immunotherapy

Novel approach will aid scientists in optimizing SNAs as therapeutic vaccines to treat cancer.

Скрыть анонс
23:43 Phys.orgNew machine learning technique rapidly analyzes nanomedicines for cancer immunotherapy

Spherical nucleic acids are a class of personalized medicines for treating cancer and other diseasesSNAs are challenging to optimize because their structures can vary in many waysNorthwestern University team developed a library approach and machine learning to rapidly synthesize, analyze and select for potent SNA medicines

Скрыть анонс
21:27 News-Medical.NetAnti-cancer immunotherapy could be used to fight HIV

Researchers at the University of Montreal Hospital Research Centre have shown that immunotherapy treatments against cancer could reduce the amount of virus that persists in people on triple therapy.

Скрыть анонс
18.02.2019
11:07 News-Medical.NetCombination of PARP inhibitor and immunotherapy results in tumor regression in SCLC mouse models

Researchers at The University of Texas MD Anderson Cancer Center have discovered that a combination of immune checkpoint blockade and targeted therapies that block normal DNA damage repair achieved significant tumor regression in mouse models of small cell lung cancer, suggesting a promising new approach for treating patients with this aggressive cancer.

Скрыть анонс
07:52 News-Medical.NetColumbia researchers unravel why some glioblastomas respond to immunotherapy

Columbia researchers have learned why some glioblastomas--the most common type of brain cancer--respond to immunotherapy. The findings could help identify patients who are most likely to benefit from treatment with immunotherapy drugs and lead to the development of more broadly effective treatments.

Скрыть анонс
17.02.2019
01:46 CNN HealthImmunotherapies could change kidney cancer care, studies suggest

The way doctors typically approach kidney cancer treatment could be evolving.

Скрыть анонс
15.02.2019
18:04 FierceBiotech.comNovel immunotherapy prevents cervical, lung cancer in mice

Researchers at the University of Louisville were testing a protein-based molecule they originally developed to boost the power of T cells in treating cancer when they made a surprising discovery: The drug protected normal mice from developing cancer in the first place.

Скрыть анонс
12.02.2019
12:22 News-Medical.NetInhibiting tuberculosis-induced cell death with immunotherapy

Tuberculosis treatment still entails the intake several antibiotics over a period of many months and is torturous for many patients. The pathogen's increasing multidrug resistance additionally complicates this lengthy treatment, and side effects frequently lead to a discontinuation of treatment and high mortality rates.

Скрыть анонс
05:52 News-Medical.NetImmunotherapy drug can be effective in treating patients with recurrent brain tumors

A UCLA-led study suggests that for people with recurrent glioblastoma, administering an immunotherapy drug before surgery is more effective than using the drug afterward.

Скрыть анонс
11.02.2019
23:12 Google news HealthImmunotherapy may help patients with the kind of cancer that killed John McCain - Washington Post

Immunotherapy may help patients with the kind of cancer that killed John McCain  Washington Post Glioblastoma — the aggressive brain cancer that killed Sen. John McCain, Sen. Ted Kennedy and Beau Biden, son of Vice President Joe Biden — is among the ...
View full coverage on Google News

Скрыть анонс
23:12 Google news Sci/TechImmunotherapy may help patients with the kind of cancer that killed John McCain - Washington Post

Immunotherapy may help patients with the kind of cancer that killed John McCain  Washington Post Glioblastoma — the aggressive brain cancer that killed Sen. John McCain, Sen. Ted Kennedy and Beau Biden, son of Vice President Joe Biden — is among the ...
View full coverage on Google News

Скрыть анонс
11:18 News-Medical.NetImmunotherapy may be better than chemotherapy for Merkel cell carcinoma

The first study of the immunotherapy drug pembrolizumab as the initial treatment for patients with a rare but aggressive form of skin cancer known as Merkel cell carcinoma reports better responses and longer survival than expected with conventional chemotherapy.

Скрыть анонс
08.02.2019
09:33 News-Medical.NetImmunotherapy drug found to be effective in patients with advanced Merkel cell carcinoma

A multi-center phase II clinical trial investigating pembrolizumab as a first-line and programmed cell death-1 therapy in patients with advanced Merkel cell carcinoma reports lasting tumor control, generally manageable side effects and improved overall survival.

Скрыть анонс
07.02.2019
22:37 ScienceDaily.comImmunotherapy appears better than chemotherapy for aggressive type of skin cancer

The first study of the immunotherapy drug pembrolizumab as the initial treatment for patients with a rare but aggressive form of skin cancer known as Merkel cell carcinoma reports better responses and longer survival than expected with conventional chemotherapy.

Скрыть анонс
06.02.2019
20:08 ScienceDaily.comCombination treatment, diabetes drug and immunotherapy, may help to fight breast cancer

Researchers in Finland have discovered a drug combination that collaborates with the cancer cells' own MYC oncoprotein, which in large quantities causes self-destruction of the cancer cells. When this combination is enhanced with immune system-boosting anti-PD-1 therapy, a more effective and long-lasting therapeutic effect can be seen in mice. These findings pave the way for new treatment combination strategies to harness the body's natural defenses to fight cancer.

Скрыть анонс
05.02.2019
18:58 CancerNetwork.comEmerging Immunotherapy Approaches For Urothelial Cancer

Cancer Network spoke with Dr. Petros Grivas about emerging immunotherapy approaches for the treatment of advanced urothelial cancer.

Скрыть анонс
18:46 Reuters.com HealthGSK pays up to $4.2 billion for Merck KGaA cancer immunotherapy

GlaxoSmithKline bolstered its cancer drug development pipeline on Tuesday, agreeing to pay up to 3.7 billion euros ($4.2 billion) to Germany's Merck KGaA for the rights to a next-generation immunotherapy.

Скрыть анонс
18:44 ReutersGSK pays up to $4.2 billion for Merck KGaA cancer immunotherapy

GlaxoSmithKline bolstered its cancer drug development pipeline on Tuesday, agreeing to pay up to 3.7 billion euros ($4.2 billion) to Germany's Merck KGaA for the rights to a next-generation immunotherapy.

Скрыть анонс
16:33 Reuters.com HealthMerck KGaA wins GSK for immunotherapy deal worth up to $4.2 billion

GlaxoSmithKline bolstered its cancer drug development pipeline on Tuesday, agreeing to pay up to 3.7 billion euros ($4.22 billion) to Germany's Merck KGaA for the rights to a novel immunotherapy.

Скрыть анонс
15:38 Reuters.com HealthMerck KGaA wins GSK for immunotherapy deal worth up to $4.2 billion

GlaxoSmithKline bolstered its cancer drug development pipeline, agreeing to pay up to 3.7 billion euros ($4.22 billion) to Germany's Merck KGaA for the rights to a novel immunotherapy.

Скрыть анонс
01:02 CancerNetwork.comEmerging Immunotherapy Approaches For Urothelial Cancer

Cancer Network spoke with Dr. Petros Grivas about emerging immunotherapy approaches for the treatment of advanced urothelial cancer.

Скрыть анонс
30.01.2019
23:44 Technology.orgMachine Learning Finds Multiple Factors Underlie Cancer Immunotherapy Success

A University of Maryland-led research team is using a branch of artificial intelligence known as machine learning to

Скрыть анонс
28.01.2019
23:20 Nanowerk.comResearchers investigate coated Prussian blue nanoparticles for cancer immunotherapies

The researchers will work with Prussian blue nanoparticles (PBNPs) coated with immunological signals, used in combination with checkpoint inhibitors.

Скрыть анонс
First← Previous12345678910Previous →Last